Loading the company…
Loading the company…
㈜학메디칼
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2015. Industry: Wholesale & Retail. Revenue for 2025 was ₩32.1bn. It has 24 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2022-09-30 · latest registration 2023-02-13 · newest first
본 발명은 검사 대상자의 비인두로부터 검체를 채취하는 검체 채취 면봉, 검체로부터 코로나바이러스를 추출하기 위한 추출 버퍼가 담긴 추출용 용기, 상기 추출 버퍼에 상기 검체 채취 면봉을 침지시켜 얻어진 검출액을 적가하는 검출액 투입부와 코로나 바이러스의 감염 여부를 시각적으로 나타내는 식별부를 구비한 진단 본체를 포함하는, 코로나 바이러스(SARS-CoV-2) 감염 진단 키트에 사용되는 검체 채취용 조성물로서, 생리 식염수 100 중량부, 폴리메틸메타크릴레이트(Polymethylmethacrylate, PMMA) 20 내지 30 중량부, 히알루론산 10 내지 15 중량부 및 펙틴 5 내지 7 중량부를 포함하는 코로나 바이러스 감염 진단 키트에 사용되는 검체 채취용 조성물 및 이를 이용한 코로나 바이러스 감염 진단 키트에 관한 것이다.
본 발명은 낮은 농도의 SARS-CoV-2 바이러스의 검출이 가능하도록, 면역 반응을 증폭시킬 수 있는 복합 구조체를 활용하여, 진단 키트에 고정된 검출 확인 입자가 복합 구조체의 일부 및/또는 복합 구조체의 내부에 내장된 나노 입자와 반응하여, 낮은 농도의 SARS-CoV-2 바이러스도 검출이 가능하게 하는 SARS-CoV-2 바이러스 검출용 조성물, 이를 이용한 SARS-CoV-2 바이러스 진단 키트 및 이를 이용한 SARS-CoV-2 바이러스 검출 방법에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 30.6 | 32.1 |
| Cost of sales | 25.2 | 25.7 |
| Gross profit (loss) | 5.4 | 6.5 |
| Selling, general and administrative expenses | 8.2 | 6.1 |
| Operating income (loss) | (2.9) | 0.4 |
| Non-operating income | 0.4 | 0.1 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.1 | 0.0 |
| Other | 0.3 | 0.0 |
| Non-operating expenses | 0.1 | 0.3 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.1 | 0.1 |
| Other | — | 0.1 |
| Profit (loss) before tax | (2.5) | 0.2 |
| Income tax expense | 0.5 | 0.1 |
| Net income (loss) | (3.1) | 0.1 |
Revenue ₩32.1bn, up 5.0% YoY.
Operating margin 1.1% (prior -9.4%).
Net income ₩0.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06